Inhibitory effects of TTP sera on binding of anti‐platelet glycoprotein II<sub>b</sub>‐III<sub>a</sub> monoclonal antibodies to human vascular endothelial cells
この論文をさがす
説明
<jats:title>Abstract</jats:title><jats:p>The binding of anti‐human platelet glycoprotein (GP) II<jats:sub>b</jats:sub>III<jats:sub>a</jats:sub> monoclonal antibodies to human umbilical vein endothelial cells (HUVE) was studied. Scatchard analysis using <jats:sup>125</jats:sup>I‐anti‐platelet GPII<jats:sub>b</jats:sub>‐III<jats:sub>a</jats:sub> monoclonal antibody showed that the maximum binding capacity (B max) was 8 × 10<jats:sup>4</jats:sup>/cell and Kd was 40.2 nM. The binding rate of <jats:sup>125</jats:sup>I‐anti‐platelet GPII<jats:sub>b</jats:sub>III<jats:sub>a</jats:sub> monoclonal antibodies to HUVE treated with TTP sera was 11.6 ± 2.8%, compared with the 24.0 ± 7.5% observed for HUVE treated with normal sera. These findings showed that there are GPII<jats:sub>b</jats:sub>‐III<jats:sub>a</jats:sub> on HUVE and that TTP sera may contain anti‐platelet GPII<jats:sub>b</jats:sub>III<jats:sub>a</jats:sub> antibodies.</jats:p>
収録刊行物
-
- American Journal of Hematology
-
American Journal of Hematology 25 115-118, 1987-05-01
Wiley